Compare Merck & Co., Inc. (MRK) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs PulteGroup, Inc. — how do they compare? Merck & Co., Inc. trades at $133.12 (market cap $321.77B), while PulteGroup, Inc. trades at $129.92 (market cap $25.22B). The key difference: Merck & Co., Inc. is far larger — about 12.8× PulteGroup, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | PHM | |
|---|---|---|
Market Cap | $321.77B | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $131.84 | $142.56 |
52-Week Low | $77.60 | $110.11 |
Enterprise Value | $368.53B | $25.64B |
Dividend Yield | 2.61% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
PulteGroup (PHM) trades at $129.35, down 0.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $2.48, beating estimates, but revenue and margins face pressure. Analyst consensus is a Moderate Buy with a $137.20 price target, and recent news highlights operational expansion into Northwest Florida and workplace recognition.
The outlook remains cautiously optimistic supported by a solid balance sheet and community growth, though margin compression and housing market affordability challenges present near-term risks. The stock offers value with a P/E of 13.53, but investors should monitor earnings consistency and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
